Sign in or create an account to add this stock to your watchlist.
About Haemonetics (NYSE:HAE)
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer system, a blood diagnostic instrument that measure a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver system, a surgical blood salvage system for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it offers SafeTrace Tx, a software solution that manages blood product inventory and transfusion, as well as performs patient cross-matching; and BloodTrack suite of solutions for managing, tracking, and controlling blood products from the hospital blood center through to transfusion to the patient. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:HAE
CUSIP40502410
Phone781-848-7100
Debt
Debt-to-Equity Ratio0.08
Current Ratio1.35
Quick Ratio0.94
Price-To-Earnings
Trailing P/E Ratio48.54
Forward P/E Ratio41.07
P/E Growth4.11
Sales & Book Value
Annual Sales$903.92 million
Price / Sales5.37
Cash Flow$3.5360 per share
Price / Cash25.67
Book Value$14.08 per share
Price / Book6.45
Profitability
EPS (Most Recent Fiscal Year)$1.87
Net Income$45.57 million
Net Margins5.04%
Return on Equity12.71%
Return on Assets7.89%
Miscellaneous
Employees3,107
Outstanding Shares53,450,000
Haemonetics (NYSE:HAE) Frequently Asked Questions
What is Haemonetics' stock symbol?
Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How will Haemonetics' stock buyback program work?
Haemonetics announced that its Board of Directors has initiated a share buyback plan on Tuesday, February 6th 2018, which permits the company to repurchase $260,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued.
How were Haemonetics' earnings last quarter?
Haemonetics (NYSE:HAE) posted its quarterly earnings data on Tuesday, May, 8th. The medical instruments supplier reported $0.43 EPS for the quarter, meeting analysts' consensus estimates of $0.43. The medical instruments supplier earned $233.55 million during the quarter, compared to the consensus estimate of $226.63 million. Haemonetics had a net margin of 5.04% and a return on equity of 12.71%. The business's revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.39 earnings per share. View Haemonetics' Earnings History.
When is Haemonetics' next earnings date?
What guidance has Haemonetics issued on next quarter's earnings?
Haemonetics updated its FY19 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $2.00-2.30 for the period, compared to the Thomson Reuters consensus estimate of $2.09.
What price target have analysts set for HAE?
6 Wall Street analysts have issued 12-month price objectives for Haemonetics' stock. Their predictions range from $50.00 to $100.00. On average, they expect Haemonetics' stock price to reach $81.40 in the next year. View Analyst Ratings for Haemonetics.
What are Wall Street analysts saying about Haemonetics stock?
Here are some recent quotes from research analysts about Haemonetics stock:
- 1. Morgan Stanley analysts commented, "We are maintaining our Outperform rating for REGENXBIO. Today, after market close, the company reported 1Q18 results and provided an update on its pipeline. Key takeaways include: 1) all programs remain on track, with topline data from both the wet AMD and HoFH trials expected in late 2018; and 2) the two MPS programs are slated to dose the first patients in mid-2018. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $336 million pro forma, we continue to recommend REGENXBIO shares to risk-tolerant investors." (5/9/2018)
- 2. According to Zacks Investment Research, "Over the past three months, Haemonetics has been outpeforming its industry. Haemonetics has been gaining on continued momentum in new business generation and geographical expansion. We are upbeat about Haemonetics’ consistent growth in the Plasma franchise. Strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth. The company is now focusing on the development and launch of NexSys PCS plasmapheresis system. The company’s strong cash position boosts investors’ confidence. The expansion in both gross and operating margin buoys optimism. The raised fiscal 2018 adjusted earnings guidance is also impressive. However, we are disappointed with the fact that despite encouraging growth at the Plasma and Hospitals segment, the company’s sluggish Blood Center business moderated overall growth in the reporting cycle." (5/4/2018)
Are investors shorting Haemonetics?
Haemonetics saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 884,267 shares, a decrease of 32.0% from the March 30th total of 1,300,931 shares. Based on an average daily trading volume, of 435,043 shares, the short-interest ratio is presently 2.0 days. Approximately 1.7% of the shares of the company are short sold.
Who are some of Haemonetics' key competitors?
Some companies that are related to Haemonetics include Abiomed (ABMD), ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Penumbra (PEN), Cantel Medical (CMD), Insulet (PODD), Globus Medical (GMED), Merit Medical Systems (MMSI), NovoCure (NVCR), NuVasive (NUVA), Nevro (NVRO) and iRhythm (IRTC).
Who are Haemonetics' key executives?
Haemonetics' management team includes the folowing people:
- Mr. Christopher Simon, Chief Exec. Officer, Pres and Director (Age 54)
- Mr. William P. Burke, Chief Financial Officer and Exec. VP
- Mr. Neil Ryding, Exec. VP of Global Operations (Age 57)
- Mr. Dan Goldstein, Principal Accounting Officer, VP & Corp. Controller (Age 41)
- Mr. Gerard J. Gould, VP of Investor Relations (Age 64)
Has Haemonetics been receiving favorable news coverage?
News headlines about HAE stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Haemonetics earned a daily sentiment score of 0.13 on Accern's scale. They also gave news stories about the medical instruments supplier an impact score of 47.20 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Haemonetics' major shareholders?
Haemonetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.96%), Wells Fargo & Company MN (3.58%), Neuberger Berman Group LLC (3.25%), Dimensional Fund Advisors LP (2.90%), Victory Capital Management Inc. (2.82%) and Millennium Management LLC (2.21%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Ronald Merriman, Susan Bartlett Foote and Willaim P Burke. View Institutional Ownership Trends for Haemonetics.
Which institutional investors are selling Haemonetics stock?
HAE stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Point72 Asset Management L.P., Neuberger Berman Group LLC, Wells Fargo & Company MN, Segall Bryant & Hamill LLC, WINTON GROUP Ltd, Royal Bank of Canada and Schwab Charles Investment Management Inc.. Company insiders that have sold Haemonetics company stock in the last year include Dan Goldstein, Jacqueline Scanlan, Mark W Kroll, Michelle L Basil, Pedro P Granadillo, Ronald G Gelbman, Susan Bartlett Foote and Willaim P Burke. View Insider Buying and Selling for Haemonetics.
Which institutional investors are buying Haemonetics stock?
HAE stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., BlackRock Inc., Columbus Circle Investors, OppenheimerFunds Inc., Federated Investors Inc. PA, Picton Mahoney Asset Management and Allianz Asset Management GmbH. View Insider Buying and Selling for Haemonetics.
How do I buy shares of Haemonetics?
Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Haemonetics' stock price today?
One share of HAE stock can currently be purchased for approximately $90.77.
How big of a company is Haemonetics?
Haemonetics has a market capitalization of $4.86 billion and generates $903.92 million in revenue each year. The medical instruments supplier earns $45.57 million in net income (profit) each year or $1.87 on an earnings per share basis. Haemonetics employs 3,107 workers across the globe.
How can I contact Haemonetics?
Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]
MarketBeat Community Rating for Haemonetics (HAE)
MarketBeat's community ratings are surveys of what our community members think about Haemonetics and other stocks. Vote "Outperform" if you believe HAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Haemonetics (NYSE:HAE) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Haemonetics in the last 12 months. Their average twelve-month price target is $81.40, suggesting that the stock has a possible downside of 10.32%. The high price target for HAE is $100.00 and the low price target for HAE is $50.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.67 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $81.40 | $70.00 | $70.00 | $51.20 |
| Price Target Upside: | 10.32% downside | 2.13% upside | 2.13% upside | 5.60% downside |
Haemonetics (NYSE:HAE) Consensus Price Target History
Haemonetics (NYSE:HAE) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Haemonetics (NYSE:HAE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Haemonetics (NYSE HAE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.20%
Institutional Ownership Percentage: 97.34%
Haemonetics (NYSE HAE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/6/2018 | Dan Goldstein | VP | Sell | 518 | $54.65 | $28,308.70 | 4,002 |  |
| 3/6/2018 | Jacqueline Scanlan | SVP | Sell | 114 | $72.23 | $8,234.22 | | |
| 3/6/2018 | Michelle L. Basil | EVP | Sell | 389 | $72.23 | $28,097.47 | | |
| 1/2/2018 | Mark W Kroll | Director | Sell | 7,118 | $63.00 | $448,434.00 | 33,881 | |
| 12/1/2017 | Pedro P Granadillo | Director | Sell | 7,118 | $57.06 | $406,153.08 | 31,663 | |
| 11/16/2017 | Ronald G Gelbman | Director | Sell | 5,440 | $56.69 | $308,393.60 | | |
| 11/14/2017 | Willaim P Burke | CFO | Sell | 13,193 | $54.04 | $712,949.72 | 27,227 | |
| 11/13/2017 | Dan Goldstein | CAO | Sell | 4,691 | $54.93 | $257,676.63 | 3,747 | |
| 11/10/2017 | Susan Bartlett Foote | Director | Sell | 16,926 | $54.19 | $917,219.94 | 27,313 | |
| 5/22/2017 | Ronald Merriman | Director | Sell | 17,471 | $40.33 | $704,605.43 | 24,925 | |
| 12/12/2016 | Ronald G Gelbman | Director | Sell | 5,683 | $40.30 | $229,024.90 | 49,688 | |
| 8/17/2016 | Ronald Merriman | Director | Sell | 4,337 | $35.14 | $152,402.18 | 22,088 | |
| 8/4/2016 | Christopher Simon | CEO | Buy | 60,000 | $35.00 | $2,100,000.00 | | |
| 10/26/2015 | Byron Selman | Insider | Sell | 344 | $32.13 | $11,052.72 | 12,010 | |
| 10/26/2015 | Christopher J Lindop | CFO | Sell | 436 | $32.13 | $14,008.68 | 45,350 | |
| 10/26/2015 | Sandra Jesse | EVP | Sell | 778 | $32.13 | $24,997.14 | 20,096 | |
| 10/26/2015 | Susan M Hanlon | VP | Sell | 497 | $32.13 | $15,968.61 | 20,464 | |
| 9/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $35.15 | $230,900.35 | 147,040 | |
| 9/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $35.63 | $169,776.95 | 147,040 | |
| 8/20/2015 | Christopher J. Lindop | CFO | Sell | 4,902 | $38.49 | $188,677.98 | 38,188 | |
| 8/17/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.28 | $258,030.32 | | |
| 7/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $39.09 | $191,619.18 | | |
| 7/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.59 | $260,066.71 | | |
| 7/6/2015 | Peter M Allen | Insider | Sell | 30,494 | $40.19 | $1,225,553.86 | | |
| 7/2/2015 | Jonathan White | Insider | Sell | 2,385 | $41.14 | $98,118.90 | | |
| 6/22/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $42.51 | $208,384.02 | | |
| 6/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $42.51 | $279,248.19 | | |
| 6/10/2015 | Susan M Hanlon | VP | Sell | 6,000 | $43.00 | $258,000.00 | | |
| 6/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $41.39 | $197,223.35 | | |
| 5/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.65 | $204,168.30 | | |
| 5/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $40.74 | $194,126.10 | | |
| 4/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.55 | $203,678.10 | | |
| 4/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.51 | $212,090.15 | | |
| 3/27/2015 | Susan M Hanlon | VP | Sell | 7,000 | $43.46 | $304,220.00 | | |
| 3/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $44.26 | $216,962.52 | | |
| 3/10/2015 | Susan Bartlett Foote | Director | Sell | 11,328 | $43.84 | $496,619.52 | | |
| 3/5/2015 | Ronald G Gelbman | Director | Sell | 7,707 | $44.76 | $344,965.32 | | |
| 3/4/2015 | Ronald Merriman | Director | Sell | 14,258 | $43.80 | $624,500.40 | | |
| 3/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.41 | $211,613.65 | | |
| 2/18/2015 | Pedro P Granadillo | Director | Sell | 11,328 | $43.45 | $492,201.60 | | |
| 2/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $39.15 | $186,549.75 | | |
| 1/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $37.20 | $177,258.00 | | |
| 12/1/2014 | Brian Concannon | CEO | Sell | 4,765 | $36.72 | $174,970.80 | | |
| 11/3/2014 | Brian Concannon | CEO | Sell | 4,765 | $35.86 | $170,872.90 | | |
| 10/13/2014 | Peter M Allen | Insider | Sell | 36,426 | $35.22 | $1,282,923.72 | | |
| 8/12/2014 | Ronald Merriman | Director | Sell | 13,602 | $35.76 | $486,407.52 | | |
| 8/1/2014 | Brian Concannon | CEO | Sell | 4,380 | $35.27 | $154,482.60 | | |
| 7/7/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $35.97 | $209,956.89 | | |
| 6/12/2014 | Ronald G Gelbman | Director | Sell | 9,184 | $34.00 | $312,256.00 | | |
| 6/6/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $34.69 | $202,485.53 | | |
| 5/12/2014 | Susan Bartlett Foote | Director | Sell | 9,184 | $33.16 | $304,541.44 | 9,939 | |
| 5/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.14 | $181,764.18 | 14,901 | |
| 5/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $30.01 | $138,046.00 | 130,307 | |
| 4/28/2014 | Peter Allen | Insider | Sell | 30,000 | $30.70 | $921,000.00 | 28,950 | |
| 4/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.98 | $186,667.26 | 14,901 | |
| 4/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $32.71 | $150,466.00 | 130,307 | |
| 3/6/2014 | Ronald Gelbman | Director | Sell | 12,000 | $36.17 | $434,040.00 | 39,173 | |
| 3/3/2014 | Brian Concannon | CEO | Sell | 4,600 | $36.36 | $167,256.00 | 130,307 | |
| 2/18/2014 | Susan Hanlon | VP | Sell | 3,690 | $39.00 | $143,910.00 | 16,905 | |
| 2/7/2014 | Jonathan White | Insider | Sell | 1,880 | $38.66 | $72,680.80 | 25,166 | |
| 2/3/2014 | Brian Concannon | CEO | Sell | 7,600 | $37.63 | $285,988.00 | 130,307 | |
| 1/27/2014 | Susan Hanlon | VP | Sell | 3,206 | $38.37 | $123,014.22 | 16,905 | |
| 1/10/2014 | Susan Hanlon | VP | Sell | 4,000 | $41.80 | $167,200.00 | 16,905 | |
| 1/2/2014 | Brian Concannon | CEO | Sell | 7,600 | $41.58 | $316,008.00 | 130,307 | |
| 12/16/2013 | Susan Hanlon | VP | Sell | 4,000 | $43.50 | $174,000.00 | 16,905 | |
| 12/9/2013 | Susan Hanlon | VP | Sell | 3,138 | $43.07 | $135,153.66 | 16,905 | |
| 12/2/2013 | Brian Concannon | CEO | Sell | 7,600 | $42.31 | $321,556.00 | 130,307 | |
| 11/12/2013 | Michael Kelly | Insider | Sell | 61,400 | $39.70 | $2,437,580.00 | 10,987 | |
| 11/1/2013 | Brian Concannon | CEO | Sell | 7,600 | $39.96 | $303,696.00 | | |
| 10/14/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.41 | $56,574.00 | 11,337 | |
| 9/13/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.36 | $56,504.00 | 11,337 | |
| 9/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $39.87 | $518,310.00 | 115,798 | |
| 8/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $42.24 | $549,120.00 | | |
| 7/12/2013 | Michael P Kelly | Insider | Sell | 1,400 | $44.10 | $61,740.00 | | |
| 7/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.87 | $544,310.00 | | |
| 6/18/2013 | Christopher J Lindop | CFO | Sell | 68,628 | $42.50 | $2,916,690.00 | | |
| 6/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $42.17 | $59,038.00 | | |
| 6/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.15 | $534,950.00 | | |
| 5/21/2013 | Christopher J Lindop | CFO | Sell | 42,882 | $42.00 | $1,801,044.00 | | |
| 5/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $39.66 | $55,524.00 | | |
| 5/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $38.66 | $502,580.00 | | |
| 12/3/2012 | Brian Concannon | CEO | Sell | 13,000 | $40.75 | $529,750.00 | | |
| 11/12/2012 | Pedro P Granadillo | Director | Sell | 16,000 | $80.40 | $1,286,400.00 | | |
| 9/4/2012 | Brian Concannon | CEO | Sell | 6,500 | $73.68 | $478,920.00 | | |
| 9/4/2012 | Christopher J Lindop | CFO | Sell | 61,783 | $74.34 | $4,592,948.22 | | |
(Data available from 1/1/2013 forward)
Haemonetics (NYSE HAE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Neil Mr. Ryding Sells 351 Shares of Haemonetics (HAE) Stock
www.americanbankingnews.com - May 23 at 8:34 PM |
| Haemonetics (HAE) EVP Neil Mr. Ryding Sells 267 Shares
www.americanbankingnews.com - May 23 at 8:34 PM |
| Haemonetics (HAE) CFO Sells $39,325.16 in Stock
www.americanbankingnews.com - May 23 at 8:34 PM |
| Haemonetics (HAE) CEO Christopher Simon Sells 3,595 Shares
www.americanbankingnews.com - May 23 at 7:52 PM |
| Haemonetics (HAE) Expected to Post Quarterly Sales of $219.52 Million
www.americanbankingnews.com - May 16 at 2:20 AM |
| Zacks: Analysts Expect Haemonetics (HAE) Will Post Earnings of $0.42 Per Share
www.americanbankingnews.com - May 14 at 5:14 PM |
| Q1 2019 EPS Estimates for Haemonetics (HAE) Cut by Barrington Research
www.americanbankingnews.com - May 14 at 4:11 AM |
| Q3 2019 EPS Estimates for Haemonetics (HAE) Lifted by Barrington Research
www.americanbankingnews.com - May 11 at 11:23 AM |
| Haemonetics (HAE) Lifted to B at TheStreet
www.americanbankingnews.com - May 10 at 6:38 PM |
 | Edited Transcript of HAE earnings conference call or presentation 8-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 4:35 PM |
| Is Eaton (ETN) a Great Stock for Value Investors?
finance.yahoo.com - May 10 at 4:35 PM |
| Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates
finance.yahoo.com - May 10 at 9:41 AM |
| Haemonetics (HAE) to Post Q1 2019 Earnings of $0.40 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 10 at 8:42 AM |
| Haemonetics (HAE) Given New $95.00 Price Target at Jefferies Group
www.americanbankingnews.com - May 9 at 5:12 PM |
| Barrington Research Increases Haemonetics (HAE) Price Target to $90.00
www.americanbankingnews.com - May 9 at 3:17 PM |
| Haemonetics (HAE) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - May 9 at 3:12 PM |
 | Haemonetics (HAE) PT Raised to $63 at Craig-Hallum
www.streetinsider.com - May 9 at 9:31 AM |
 | Haemonetics 4th Quarter Fiscal 2018 Earnings Release Available on Investor ...
www.prnewswire.com - May 9 at 9:31 AM |
| Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief ...
www.prnewswire.com - May 9 at 9:31 AM |
| Q1 2019 Earnings Estimate for Haemonetics (HAE) Issued By William Blair
www.americanbankingnews.com - May 9 at 9:06 AM |
| Haemonetics (HAE) and Invuity (IVTY) Critical Survey
www.americanbankingnews.com - May 8 at 11:18 PM |
 | Haemonetics (HAE) Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 4:27 PM |
| Is It The Right Time To Buy Haemonetics Corporation (NYSE:HAE)?
finance.yahoo.com - May 8 at 4:27 PM |
| Haemonetics (HAE) Posts Earnings Results, Meets Estimates
www.americanbankingnews.com - May 8 at 10:11 AM |
| Haemonetics (HAE) Releases FY19 Earnings Guidance
www.americanbankingnews.com - May 8 at 9:52 AM |
 | BRIEF-Haemonetics Reports Qtrly Earnings Per Share Of $0.22
www.reuters.com - May 8 at 9:23 AM |
 | Haemonetics Q4 Profit Tops Estimates; Appoints Said Bolorforosh CTO
www.nasdaq.com - May 8 at 9:23 AM |
| Haemonetics: Fiscal 4Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:23 AM |
| Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology Officer
finance.yahoo.com - May 8 at 9:23 AM |
| Haemonetics 4th Quarter Fiscal 2018 Earnings Release Available on Investor Relations Website
finance.yahoo.com - May 8 at 9:23 AM |
| Haemonetics (HAE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 7 at 1:08 AM |
| Haemonetics (HAE) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 5 at 1:07 AM |
| Haemonetics (HAE) Short Interest Update
www.americanbankingnews.com - May 3 at 1:40 AM |
| Haemonetics (HAE) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 1 at 2:08 AM |
| Global Blood Collection Market 2018-2022 with Focus on Key Vendors - BD, Haemonetics, Quest Diagnostics & Thermo Fisher Scientific
finance.yahoo.com - April 30 at 4:26 PM |
| Haemonetics (HAE) Expected to Post Quarterly Sales of $224.57 Million
www.americanbankingnews.com - April 29 at 4:43 AM |
| Haemonetics (HAE) Expected to Post Earnings of $0.43 Per Share
www.americanbankingnews.com - April 27 at 3:14 AM |
| Teleflex (TFX) versus Haemonetics (HAE) Critical Contrast
www.americanbankingnews.com - April 18 at 1:20 AM |
| BidaskClub Downgrades Haemonetics (HAE) to Strong Sell
www.americanbankingnews.com - April 15 at 1:17 PM |
| Haemonetics (HAE) Lifted to Sell at BidaskClub
www.americanbankingnews.com - April 12 at 6:15 PM |
| $224.57 Million in Sales Expected for Haemonetics Co. (HAE) This Quarter
www.americanbankingnews.com - April 12 at 4:37 AM |
| Haemonetics Co. (HAE) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 12 at 1:29 AM |
| Haemonetics (HAE) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 8:27 PM |
| Haemonetics Rides High on Plasma, Blood Center Remains Weak
finance.yahoo.com - April 11 at 4:28 PM |
| Haemonetics (HAE) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 10:25 AM |
| Insider Selling: Haemonetics Co. (HAE) VP Sells 518 Shares of Stock
www.americanbankingnews.com - April 10 at 7:31 PM |
| Haemonetics Sets Date for Publishing Fourth Quarter Fiscal 2018 Results: May 8, 2018
finance.yahoo.com - April 10 at 9:54 AM |
| Zacks: Analysts Anticipate Haemonetics Co. (HAE) Will Announce Earnings of $0.43 Per Share
www.americanbankingnews.com - April 10 at 5:24 AM |
| Haemonetics (HAE) Upgraded to Strong-Buy by ValuEngine
www.americanbankingnews.com - April 10 at 12:33 AM |
| Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
finance.yahoo.com - April 2 at 4:29 PM |
Haemonetics (NYSE:HAE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Haemonetics (NYSE:HAE) Income Statement, Balance Sheet and Cash Flow Statement
Haemonetics (NYSE HAE) Stock Chart for Thursday, May, 24, 2018
Loading chart…
